- Home
- SPRY vs GLPG Comparison
SPRY vs GLPG Comparison
Compare SPRY & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRY
- GLPG
- Stock Information
- Founded
- SPRY 2015
- GLPG 1999
- Country
- SPRY United States
- GLPG Belgium
- Employees
- SPRY N/A
- GLPG N/A
- Industry
- SPRY Biotechnology: Pharmaceutical Preparations
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- SPRY Health Care
- GLPG Health Care
- Exchange
- SPRY Nasdaq
- GLPG Nasdaq
- Market Cap
- SPRY 1.8B
- GLPG 2.1B
- IPO Year
- SPRY N/A
- GLPG 2005
- Fundamental
- Price
- SPRY $11.62
- GLPG $31.53
- Analyst Decision
- SPRY Strong Buy
- GLPG Sell
- Analyst Count
- SPRY 4
- GLPG 4
- Target Price
- SPRY $28.75
- GLPG $25.33
- AVG Volume (30 Days)
- SPRY 2.3M
- GLPG 270.2K
- Earning Date
- SPRY 08-13-2025
- GLPG 10-29-2025
- Dividend Yield
- SPRY N/A
- GLPG N/A
- EPS Growth
- SPRY N/A
- GLPG N/A
- EPS
- SPRY N/A
- GLPG N/A
- Revenue
- SPRY $112,339,000.00
- GLPG $323,674,692.00
- Revenue This Year
- SPRY N/A
- GLPG N/A
- Revenue Next Year
- SPRY $182.40
- GLPG N/A
- P/E Ratio
- SPRY N/A
- GLPG N/A
- Revenue Growth
- SPRY 22367.80
- GLPG 5.43
- 52 Week Low
- SPRY $10.00
- GLPG $22.36
- 52 Week High
- SPRY $18.90
- GLPG $33.86
- Technical
- Relative Strength Index (RSI)
- SPRY 25.12
- GLPG 50.74
- Support Level
- SPRY $13.32
- GLPG $31.42
- Resistance Level
- SPRY $14.00
- GLPG $33.25
- Average True Range (ATR)
- SPRY 1.00
- GLPG 0.71
- MACD
- SPRY -0.30
- GLPG -0.10
- Stochastic Oscillator
- SPRY 9.88
- GLPG 36.92
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.